Morning Session Room 1714 OVC LLC

9:00 - 9:10 Introductory remarks

9:10 - 10:00 Guest Speaker
Jonathan Blay, School of Pharmacy, University of Waterloo, Waterloo; Department of Pathology, Dalhousie University, Halifax, NS
Two environments: The tissue microenvironment in colorectal cancer and the growing University of Waterloo environment in cancer research.

10:00 - 10:20 coffee break OVC 1707 B & C

10:20 - 10:40 Nathan Farias, Department of Biomedical Sciences, University of Guelph
Colorectal cancer cells treated with varying levels of folic acid demonstrate altered DNA methylation and variable abilities to proliferate in suspension.

10:40 - 11:00
Roman Kondra, Molecular & Cellular Biology, University of Guelph
Role of the Wnt ligand in Nkd1’s function and activation

11:00 - 11:20
Elizabeth Franks, Biomedical Science, University of Guelph
Divergent roles of Akt isoforms in insulin-like growth factor receptor-mediated lung tumorigenesis

11:20 - 11:40
Jim Petrik, Department of Biomedical Science, University of Guelph
The paradox of anti-angiogenic therapy

11:45 - 1:30 OVC LLC 1707 B & C
Poster Session and Lunch (provided)
poster presenters please attend your posters between 12:30 and 1:30
Afternoon Session Room 1714 OVC LLC

1:40 - 2:00
Jennifer Woo, Client Coordinator, Ontario Tumour Bank, Ontario Institute for Cancer Research
*Ontario Tumour Bank - An international resource for cancer researchers*

2:00 - 2:20
Courtney Schott, Pathobiology, University of Guelph
*Design and construction of tissue microarrays for discovery of prognostic markers in canine cancers*

2:20 - 2:40
Leanne Delaney, Department of Biomedical Sciences, University of Guelph
*Involvement of Mcl-1 in the response of colorectal cancer cells to DCA treatment*

2:40 - 3:00
Evan Lusty, Department of Pathobiology, University of Guelph
*Characterizing oncolytic viruses, Toll Like Receptor ligands and histone deacetylase inhibitors in the in vitro treatment of human prostate cancer*

3:00 - 3:20
Melissa Parsons-Doherty, Mona Campbell Centre for Animal Cancer, OVC HSC, University of Guelph
*The efficacy and adverse event profile of Dexamethasone, Melphalan, Actinomycin D and Cytosine Arabinoside (DMAC) chemotherapy in relapsed canine lymphoma*

3:20-3:30
*Break*

3:30 - 4:30
Keynote Speaker
Dr. David Argyle, Royal (Dick) School of Veterinary Studies and Roslin Institute, The University of Edinburgh
*Title: A funny thing happened to me on the way to malignancy: Can comparative biology inform rational cancer drug development?*

4:30 OVC LLC 1707 B & C
*Closing Reception*